Click Here to Download the Agenda
Home
The Conference
Registration
Hotel Accommodations
Abstracts
Sponsors/Exhibitors
Partners
News
About Us
General
More...
Outcomes of Participants with Diabetes in the ISCHEMIA Trials
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Digital Health Technology in Diabetes & Heart Disease
Combinations of SGLT2 Inhibitors & GLP 1 Receptor Agonists: Potential Impact on the Kidney and the Heart
Dyslipidemia – Emerging Therapies
Aspirin for Primary Prevention: Trials, Tribulations, and Trust
Antiplatelet in the Prevention and Management of ASCVD in Diabetes
Debate: Which is the Better Test? Nuclear Stress
Coronary Calcium Scoring for Risk Stratification and Guidelines
Prevention and Management of ASCVD in Diabetes
Sodium Glucose Cotransporter 2 Inhibitors in HF: Racial Differences and a Potential for Reducing Disparities
Equitably Bending the Curve: Trends and Inequities in Diabetes/CVD Outcomes
The Role of CGM in the Wide & Narrow Spectrum of Diabetes
Role of Steroidal and Non Steroidal MRA in Cardiorenal Diseases
Individualized CVOT Directed Management For Our Patients with
DM and/or CardioRenal Metabolic Diseases
LDL-C lowering and CV outcomes - Have we reached the limits yet?
The Influence of Diabetes on the Efficacy of Aspirin Therapy - Glucose Control and Acetyl Salicylic Acid
Incorporating Genetic Testing and Polygenic Risk Scores in Cardiovascular Disease Risk Assessment
CT Angiography vs Nuclear Stress Which is the Better Test? For What?
The Impact of CKD on Cardiovascular Disease
Contemporary Approach to the Management of CKD and Heart Failure
COVID-19 Outcome in Heart Transplant and Heart Failure
COVID-19 & New Onset Diabetes: Metabolic Disorders and Research Priorities
Can Type 2 Diabetes Therapies Slow Cognitive Decline? The Evidence
Hypoglycemia Impact on Comorbidities: 2022 Approach To Its Management
Contemporary Approach to Managing Diabetes – the New and the Newer
Sex Differences in
Heart Failure
Cardiovascular Impact of Race and Ethnicity in Patients With Diabetes and Obesity
Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease and Stroke
Overview: Diabetes, Kidney and Heart Disease
Management of Diabetes and CKD – Circa 2022
Big Data and Wearables for Managing Health and COVID
Prevention and Management of Stroke in Patients with Diabetes
Impact of Management of Hyperglycemia and Blood Pressure on Cardiovascular Autonomic Neuropathy
Tools to Aid Individualized Treatment for T2D
Prevalence and Prognostic Implications of Diabetic Cardiomyopathy
Would Device Treatment in Heart Failure Obviate the Need for Drug Therapy?
CVD in NAFLD: Personalizing Diagnosis and Treatment Using Machine Learning
Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum
Pathogenesis of CKD in Diabetes
Obesity Pharmacotherapy: Present and Future
Nutrition, Exercise, Sarcopenia & Central Obesity in relation to NAFLD, T2DM & CVD
ADA and KDIGO Consensus Statement on Diabetes and CKD
CVOT Update
Type 2 Diabetes Treatment Guidelines: The Good, the Bad and the Ugly
Sex Differences in Diabetes impact on ASCVD and HF
The Role of Diet in CVD, CKD, and Heart Failure
Identifying CKD Before Its Too Late
The Approach to the Management of Anemia in CKD
The 2022 ACC/AHA/HFSA Heart Failure Guidelines
CVD in Women, Ischemia Diagnosis and Menopause Hormone Theraphy
Management of Cardiovascular Risk Factors During Pregnancy